Cowen and Company’s Coherus Oncology CHRS Stock Holding History

Cowen and Company’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-7,479	Closed	-$109K	–	610
2021 Q1	$109K	Buy	+7,479	New	+$127K	0.01%	318

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Cowen and Company's CHRS Position: Q2 2021 in Review

Cowen and Company sold out of Coherus Oncology (CHRS) in Q2 2021, closing a stake of 7,479 shares — an estimated $109K sold.

Cowen and Company first reported a position in CHRS in Q1 2021 and held it in 1 quarter. The position peaked at $109K in Q1 2021. 188 funds tracked by Wall St. Rank hold CHRS as of Q2 2021.

Cowen and Company reported no remaining Coherus Oncology position as of Q2 2021 after selling out during the quarter.
Cowen and Company sold 7,479 Coherus Oncology shares in Q2 2021, an estimated $109K.
Cowen and Company first reported a position in Coherus Oncology in Q1 2021 and held it in 1 quarter.
Cowen and Company's Coherus Oncology position peaked at $109K in Q1 2021.
188 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2021.

Based on Cowen and Company's 13F filing for Q2 2021, filed 13 Aug 2021.